Enable broad development of our best-in-class programs targeting co-inhibitory receptors in RA and UC.

Generate in vitro and in vivo translational and clinical data to inform the potential differentiation of our molecules from in-class competitors and standard of care, and identify patient populations most likely to have deeper and/or more durable responses by restoring immune balance.

Facilitate the global commercialization of our programs targeting co-inhibitory receptors while retaining rights in key therapeutic areas and/or commercial markets to enable us to become a fully integrated discovery, development and commercial organization.

Continue to leverage our research platform to generate potentially best-in-class antibodies against high-value immunological targets.